Weitz & Luxenberg attorney Jared Scotto was recently named a 2023 New York Law Journal Distinguished Leader. The award honors lawyers with great performances, while…Read More
We are no longer accepting new cases.
Janssen Pharmaceuticals’ Invokana (canagliflozin) was approved by the U.S. Food and Drug Administration (FDA) in 2013. As the first in a new class of diabetes drugs called active inhibitors of sodium-glucose co-transporter-2 (SGLT2), Invokana is intended to treat type 2 diabetes, along with diet and exercise.
Invokana is thought to work by blocking glucose reabsorption into the bloodstream, thereby increasing urinary glucose excretion, and, in turn, lowering blood sugar levels in persons with elevated blood sugar concentrations. However, Invokana and SGLT2 inhibitors have been linked with serious medical conditions that could result in hospitalization or even death.
Complications Associated with Invokana and the SGLT2 Inhibitors
In 2014, Janssen Pharmaceuticals received FDA approval for another SGLT2 inhibitor, Invokamet, which combines Invokana and another type 2 diabetes drug, metformin. Together, Invokana and Invokamet accounted for more than $1.3 billion in Janssen worldwide sales in 2015.
But Invokana, Invokamet, and the other SGLT2 inhibitors have been the subject of attention from government agencies in the U.S., Canada, Europe, and other countries because of serious medical complications.
These conditions include:
- Diabetic ketoacidosis (DKA) – a condition involving too mucth acid in the blood that can result in coma, kidney and other organ injury, and death
- Serious urinary tract infections (UTIs) resulting in blood or kidney infections
- Acute kidney injury (AKI)
- Increased risk of leg, foot, and toe amputations (Invokana and Invokamet)
If you have developed any of these conditions after taking Invokana or Invokamet, or if a relative died from one of these conditions while on these drugs, you may be entitled to reimbursement for medical expenses, lost wages, and other costs.
Ready to Fight for You
Ellen Relkin will be happy to review your case.
Ellen Relkin, of Weitz & Luxenberg’s Drug and Medical Device Unit was appointed by the Honorable Brian Martinotti, of the United States District Court for the District of New Jersey, the Judge handling the entire multidistrict litigation (MDL), to serve on the Plaintiffs’ Executive Committee. In that role, Weitz & Luxenberg is serving in the leadership of the litigation.
Attorneys with Weitz & Luxenberg’s Drug and Medical Device Unit have played key roles in securing billions of dollars in verdicts and settlements for people hurt by faulty medicines or medical devices. While past results are not a guarantee of future success, Weitz & Luxenberg has the experience and resources necessary to pursue justice for clients in complex medical-related cases.
Invokana and SGLT2 Inhibitors Face Government Scrutiny
In 2015, just two years after Invokana received FDA approval, government agencies in the U.S., Canada, and the European Union began issuing a series of warnings and advisories about risks associated with Invokana and other drugs in its class.
- May 2015The FDA warned that Invokana and other SGLT2 inhibitors may lead to diabetic ketoacidosis, a serious condition that can require hospitalization. The FDA’s Canadian counterpart, Health Canada, issued a similar report in May 2016.
- May 18, 2016FDA issued a Drug Safety Communication warning the public about interim safety results from “an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes,” in patients who had taken Invokana or Invokamet.
- June 14, 2016The FDA further strengthened the warnings for Invokana, Invokamet, and another type of SGLT2 inhibitor “to include information about acute kidney injury…” The agency also called on health care professionals and patients to report Invokana and other SGLT2 inhibitor side effects to the FDA MedWatch program.
- Late 2016The FDA said it was “evaluating the need for regulatory action” after detecting a potential signal of serious risk of acute pancreatitis via adverse events reported to the FDA; that patients taking Invokana and other SGLT2 inhibitors had developed this condition. Previous studies published in 2015 had warned that drug-induced pancreatitis (DIP) “may easily be overlooked” in patients taking Invokana, and doctors should be aware of the “potentially fatal adverse effect” as Invokana is more widely prescribed.
- February 2017The European Medicines Agency (EMA) concluded its investigation of leg and foot amputations. The agency recommended that a warning on the risk of lower limb amputations – primarily toes – be included with prescribing information for SGLT2 inhibitors.
- May 16, 2017The FDA determined that “Based on new data from two large clinical trials . . . the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.”
If you have been injured after taking Invokana and Invokamet, Weitz & Luxenberg can provide a free consultation to help you understand your legal options. Weitz & Luxenberg has filed cases on behalf of numerous clients who suffered Invokana-induced amputations, diabetic ketoacidosis, coma, and acute kidney injury.
Invokana and Other SGLT2 Inhibitor-Induced Diabetic Ketoacidosis (DKA)
One of Invokana’s and the other SGLT2 inhibitors’ most widely studied adverse events is that of their relationship with diabetic ketoacidosis. Multiple studies have demonstrated patients taking Invokana or other SGLT2 inhibitors may develop DKA. Diabetic ketoacidosis results from too much acid in the blood. In severe cases, DKA can result in a coma or death.
The FDA has mandated the addition of a warning to the Invokana and other SGLT2 inhibitors’ labels regarding the risk of diabetic ketoacidosis.
The warning informs patients to seek immediate medical attention if they experience symptoms of DKA, which may include:
- Difficulty breathing
- Nausea or vomiting
- Abdominal pain
- Unusual fatigue or sleepiness
- Abdominal pain
If you were prescribed Invokana or another SGLT2 inhibitor for type 2 diabetes and were later hospitalized for diabetic ketoacidosis, Weitz and Luxenberg would like to talk to you.
Invokana and Other Injuries
Weitz & Luxenberg is also interested in talking to patients who took Invokana or Invokamet and had to be hospitalized due to a urinary tract infection resulting in a blood or kidney infection, acute kidney injury, or renal failure.
Consult your doctor before stopping any prescribed medication.
Invokana Lawsuits Filed
Multiple lawsuits claim Janssen Pharmaceuticals was aware of potential dangers, but never warned patients about the risk of kidney damage or other complications.
In December 2016, 55 lawsuits over Invokana were combined into a single multidistrict litigation (MDL) in New Jersey.
There are now more than five hundred cases pending. MDLs can speed up the legal process and save time and money by consolidating all cases for discovery and selecting a small number of cases to be tried as bellwether cases. Judge Martinotti has already conducted a “Science Day” where experts, on behalf of the parties, explained the medicine regarding DKA and acute kidney injury and Invokana and Invokamet. Weitz & Luxenberg played an integral role in selecting and working with the endocrinology expert who presented.
How Weitz & Luxenberg Can Help
You may be entitled to compensation if you took Invokana or another SGLT2 inhibitor and were then hospitalized for DKA, acute kidney injury, amputation, or for a serious urinary tract infection that resulted in a blood or kidney infection. You may also be entitled to compensation if a relative died after taking Invokana or another SGLT2 inhibitor.
We can help you determine your legal options, beginning with a free consultation.
Contact Weitz & Luxenberg at , or fill out the contact form on this page and one of our representatives will be in touch with you shortly.